New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:37 EDTLIFE, ZLTQ, BIG, ILMN, GPREHigh option volume stocks: LIFE ZLTQ BIG ILMN GPRE
News For LIFE;ZLTQ;BIG;ILMN;GPRE From The Last 14 Days
Check below for free stories on LIFE;ZLTQ;BIG;ILMN;GPRE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
12:18 EDTBIGOn The Fly: Midday Wrap
Subscribe for More Information
11:28 EDTBIGOptions with decreasing implied volatility
Options with decreasing implied volatility: ITMN EXPR DSW ARUN ANF SWHC BIG TSL BBY PSEC
10:34 EDTBIGBig Lots slumps as retailer predicts Q3 EPS loss
Subscribe for More Information
09:22 EDTBIGOn The Fly: Pre-market Movers
Subscribe for More Information
08:21 EDTBIGBig Lots sees Q4 comps in low-single digit range
Subscribe for More Information
08:16 EDTBIGBig Lots sees Q4 EPS from cont. operations $1.40-$1.76
08:14 EDTBIGBig Lots sees Q3 EPS from cont. ops (4c)-(10c), consensus (4c)
Subscribe for More Information
06:49 EDTBIGBig Lots up 1.3% after reporting Q2 results, $250M share repurchase program
06:21 EDTBIGBig Lots announces new $250M share repurchase program
Subscribe for More Information
06:20 EDTBIGBig Lots narrows FY14 EPS view to $2.40-$2.50 from $2.35-$2.50, consensus $2.48
Subscribe for More Information
06:17 EDTBIGBig Lots reports Q2 continuing operations EPS 31c, consensus 30c
Subscribe for More Information
August 28, 2014
15:47 EDTBIGBig Lots technical notes ahead of results
Subscribe for More Information
15:22 EDTBIGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Big Lots (BIG), consensus 30c.
13:26 EDTBIGBig Lots September volatility elevated into Q2 and outlook
Subscribe for More Information
August 27, 2014
06:46 EDTBIGBig Lots outlook positive into Q2 results, says Piper Jaffray
Subscribe for More Information
August 21, 2014
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
August 19, 2014
11:32 EDTILMNLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use